4.5 Article

Fat Metaplasia and Backfill Are Key Intermediaries in the Development of Sacroiliac Joint Ankylosis in Patients With Ankylosing Spondylitis

Journal

ARTHRITIS & RHEUMATOLOGY
Volume 66, Issue 11, Pages 2958-2967

Publisher

WILEY
DOI: 10.1002/art.38792

Keywords

-

Categories

Funding

  1. Spondyloarthritis Research Consortium of Canada
  2. Danish Council for Independent Research in the Medical Sciences
  3. Alberta Innovates Health Solutions

Ask authors/readers for more resources

Objective. Fat metaplasia in bone marrow on T1-weighted magnetic resonance imaging (MRI) scans may develop after resolution of inflammation in patients with ankylosing spondylitis (AS) and may predict new bone formation in the spine. Similar tissue, termed backfill, may also fill areas of excavated bone in the sacroiliac (SI) joints and may reflect resolution of inflammation and tissue repair at sites of erosions. The purpose of this study was to test our hypothesis that SI joint ankylosis develops following repair of erosions and that tissue characterized by fat metaplasia is a key intermediary step in this pathway. Methods. We used the Spondyloarthritis Research Consortium of Canada (SPARCC) SI structural lesion score (SSS) method to assess fat metaplasia, erosions, backfill, and ankylosis on MRIs of the SI joints in 147 patients with AS monitored for 2 years. Univariate and multivariate regression analyses focused first on identifying significant MRI predictors of new backfill and fat metaplasia. We then assessed the role of backfill and fat metaplasia in the development of new ankylosis. All analyses were adjusted for demographic features, treatment, and baseline and 2-year change in SSS values for parameters of inflammation and MRI structural lesions. Results. Resolution of inflammation and reduction of erosions were each independently associated with the development of new backfill and fat metaplasia at 2 years on multivariate analyses. Multivariate regression analysis that included demographic features, baseline and 2-year change in parameters of inflammation and MRI structural lesion showed that reduction in erosions (P = 0.0005) and increase in fat metaplasia (P = 0.002) at 2 years was each independently associated with the development of new ankylosis. Conclusion. Our data support a disease model whereby ankylosis develops following repair of erosions, and fat metaplasia and backfill are key intermediary steps in this pathway.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Rheumatology

Response to: 'Correspondence on 'MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group'' by Jibri et al

Walter P. Maksymowych, Robert G. W. Lambert, Mikkel ostergaard, Xenofon Baraliakos

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension

Desiree van der Heijde, Maxime Dougados, Walter P. Maksymowych, Gina Bergman, Sean P. Curtis, Anjela Tzontcheva, Susan Huyck, George Philip, Joachim Sieper

Summary: In this study, the long-term efficacy and safety of golimumab (GLM) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) were evaluated. It was found that GLM treatment provided sustained improvement in clinical efficacy at 52 weeks and was well tolerated.

RHEUMATOLOGY (2022)

Article Rheumatology

Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis

Uta Kiltz, Annelies Boonen, Desiree van der Heijde, Wilson Bautista-Molano, Ruben Burgos Vargas, Praveena Chiowchanwisawakit, Bassel El-Zorkany, Inna Gaydukova, Pal Geher, Laure Gossec, Michele Gilio, Simeon Grazio, Jieruo Gu, Muhammad Asim Khan, Tae-Jong Kim, Walter P. Maksymowych, Helena Marzo-Ortega, Victoria Navarro-Compan, Salih Ozgocmen, Dimos Patrikos, Fernando Manuel Pimentel-Santos, John Reveille, Michael Schirmer, Simon Stebbings, Filip Van den Bosch, Ulrich Weber, Juergen Braun

Summary: This study developed an Environmental contextual factors (EF) Item Set (EFIS) to accompany the Assessment of SpondyloArthritis international Society Health Index (ASAS HI), aiming to interpret ASAS HI results by exploring the interaction between health conditions and contextual factors.

RHEUMATOLOGY (2022)

Article Rheumatology

Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)

Walter P. Maksymowych, Mikkel Ostergaard, Robert Landewe, William Barchuk, Ke Liu, Chantal Tasset, Leen Gilles, Thijs Hendrikx, Robin Besuyen, Xenofon Baraliakos

Summary: The study found that filgotinib significantly reduced SI joint erosion and increased backfill scores in AS patients, suggesting potential prognostic implications for ankylosis development.

RHEUMATOLOGY (2022)

Article Rheumatology

Improving the design of RCTs in non-radiographic axial spondyloarthritis

Walter P. Maksymowych, Robert G. W. Lambert, Liron Caplan, Filip E. van den Bosch, Mikkel ostergaard

Summary: The current RCT design does not fully utilize MRI to select nr-axSpA patients who best demonstrate differences in clinical response rates between active drug and placebo therapies. Future studies should incorporate revised patient inclusion criteria based on expanded MRI evaluation and data-driven definitions of a positive MRI to improve discrimination between therapies.

NATURE REVIEWS RHEUMATOLOGY (2022)

Article Rheumatology

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study

Desiree van der Heijde, Lianne S. Gensler, Walter P. Maksymowych, Robert Landewe, Martin Rudwaleit, Lars Bauer, Thomas Kumke, Mindy Kim, Simone Emanuele Auteri, Bengt Hoepken, Atul Deodhar

Summary: The 52-week results from the C-axSpAnd study demonstrate the long-term safety and efficacy of Certolizumab pegol (CZP) in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). CZP treatment for up to 3 years is well tolerated and leads to sustained clinical improvement.

RMD OPEN (2022)

Article Rheumatology

Instrument selection for the ASAS core outcome set for axial spondyloarthritis

Victoria Navarro-Compan, Anne Boel, Annelies Boonen, Philip J. Mease, Maxime Dougados, Uta Kiltz, Robert B. M. Landewe, Xenofon Baraliakos, Wilson Bautista-Molano, Praveena Chiowchanwisawakit, Hanne Dagfinrud, Lara Fallon, Marco Garrido-Cumbrera, Lianne Gensler, Bassel Kamal ElZorkany, Nigil Haroon, Yu Heng Kwan, Pedro M. Machado, Walter Maksymowych, Anna Molto, Natasha de Peyrecave, Denis Poddubnyy, Mikhail Protopopov, Sofia Ramiro, In-Ho Song, Salima van Weely, Desiree van der Heijde

Summary: This study aims to define the instruments for the Assessment of SpondyloArthritis international Society-Outcomes Measures in Rheumatology core domain set for axial spondyloarthritis (axSpA). The study selected core outcome instruments through a systematic literature review and assessment of the instruments' psychometric properties. Additionally, the study endorsed additional instruments to enhance the evaluation of axSpA trials.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohort

Mikhail Protopopov, Fabian Proft, Stephanie Wichuk, Pedro M. Machado, Robert G. Lambert, Ulrich Weber, Susanne Juhl Pedersen, Mikkel Ostergaard, Joachim Sieper, Martin Rudwaleit, Xenofon Baraliakos, Walter P. Maksymowych, Denis Poddubnyy

Summary: This study compares the ability of MRI and conventional radiography to detect structural lesions indicative of axSpA.

RHEUMATOLOGY (2023)

Article Rheumatology

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

Desiree van der Heijde, Atul Deodhar, Walter P. Maksymowych, Joachim Sieper, Filip Van den Bosch, Tae-Hwan Kim, Mitsumasa Kishimoto, Andrew J. Ostor, Bernard Combe, Yunxia Sui, Yuanyuan Duan, Peter K. Wung, In-Ho Song

Summary: Upadacitinib 15 mg once daily demonstrated sustained and consistent efficacy in the long-term treatment of active ankylosing spondylitis. It effectively inhibited radiographic progression and no new safety concerns were identified in the clinical trial.

RMD OPEN (2022)

Article Rheumatology

Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis

Walter P. Maksymowych, Xenofon Baraliakos, Robert G. Lambert, Robert Landewe, David Sandoval, Hilde Carlier, Jeffrey Lisse, Xiaoqi Li, Maja Hojnik, Mikkel Ostergaard

Summary: Ixekizumab treatment in patients with non-radiographic axial spondyloarthritis showed significant reductions in erosions and increases in fat lesions and backfill in the sacroiliac joints, suggesting an early repair process.

LANCET RHEUMATOLOGY (2022)

Review Rheumatology

Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

Ying-Ying Leung, Tatiana V. Korotaeva, Liliana Candia, Susanne Juhl Pedersen, Wilson Bautista Molano, Eric M. Ruderman, Radjesh Bisoendial, Rodolfo Perez-Alamino, Wendy Olsder, Burkhard Moeller, Simeon Grazio, Tania Gudu, Girish M. Mody, Carlos Pineda, Helena Raffayova, Sherry Rohekar, Claudia Goldenstein-Schainberg, Sergio R. Gutierrez Urena, Julio Cesar Casasola Vargas, Bhowmik Meghnathi, Roopa Prasad, Pascal Richette, Jose Roberto S. Miranda, Nikolas Malliotis, Ulla Lindqvist, David Simon, Amara Ezeonyeli, Enrique R. Soriano, Oliver FitzGerald

Summary: The objective of this study was to provide evidence for the efficacy and safety of therapeutic options for the peripheral arthritis domain of PsA for the revised 2021 GRAPPA treatment recommendations. Evidence was derived from new RCTs and recommendations were made for different patient groups based on their treatment history and response. Different classes of therapeutic options were strongly recommended for different patient groups.

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis-results from two randomized controlled trials

Helena Port, Signe Holm Nielsen, Peder Frederiksen, Sofie Falkenlove Madsen, Anne-Christine Bay-Jensen, Inge Juul Sorensen, Bente Jensen, Anne Gitte Loft, Ole Rintek Madsen, Mikkel Ostergaard, Susanne Juhl Pedersen

Summary: This study investigated whether extracellular matrix (ECM) blood-based biomarkers reflect the pharmacodynamic effect and response to TNF-a inhibitor therapy in patients with axial spondyloarthritis (axSpA). The results showed that ECM metabolites exhibited a pharmacodynamic effect and were associated with ASDAS response.

ARTHRITIS RESEARCH & THERAPY (2023)

Article Rheumatology

Comparative validation of the knee inflammation MRI scoring system and the MRI osteoarthritis knee score for semi-quantitative assessment of bone marrow lesions and synovitis-effusion in osteoarthritis: an international multi-reader exercise

Walter P. Maksymowych, Jacob L. Jaremko, Susanne J. Pedersen, Iris Eshed, Ulrich Weber, Andrew McReynolds, Paul Bird, Stephanie Wichuk, Robert G. Lambert

Summary: This study compared the performance of two new web-based MRI scoring systems (KIMRISS and MOAKS) in quantification of bone marrow lesions (BML) and synovitis-effusion (S-E). The results showed that KIMRISS had higher reliability and usability in evaluating BML and synovitis. Both methods should be further compared in clinical trials of new therapies for OA.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2023)

Article Medicine, General & Internal

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy, Walter P. Maksymowych, Desiree van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Ricardo Blanco, Yuanyuan Duan, Yihan Li, Aileen L. Pangan, Peter Wung, In-Ho Song

Summary: Upadacitinib demonstrates significant efficacy and safety in patients with non-radiographic axial spondyloarthritis.

LANCET (2022)

Article Rheumatology

Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study

Philip C. Robinson, Walter P. Maksymowych, Lianne S. Gensler, Stephen Hall, Martin Rudwaleit, Bengt Hoepken, Lars Bauer, Thomas Kumke, Mindy Kim, Natasha de Peyrecave, Atul Deodhar

Summary: This study demonstrates that CZP treatment can provide clinical responses in patients with nr-axSpA across MRI+/CRP+, MRI-/CRP+, and MRI+/CRP- subgroups.

ACR OPEN RHEUMATOLOGY (2022)

No Data Available